Stockreport

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

Ironwood Pharmaceuticals, Inc. - Class A  (IRWD) 
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.ironwoodpharma.com
PDF – LINZESS® (linaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% year-over-year; EUTRx demand growth increased 12% year-over-year –– GAAP net incom [Read more]